Genexine to Present at the 35th J.P. Morgan Healthcare Conference

SEONGNAM, South Korea–(BUSINESS WIRE)– Genexine
Inc. (KOSDAQ: 095700), a clinical stage biotechnology company
developing innovative biologics focused on immuno-oncology and
metabolic/autoimmune diseases, today announced that Dr.
H. Michael Keyoung, CEO and President of Genexine, will present at
the J.P. Morgan 35^th Annual Healthcare Conference Emerging
Markets Track on January 11th at the Westin St. Francis Hotel, San
Francisco. The J.P. Morgan Healthcare Conference is one of the
healthcare industry’s biggest events of the year and it brings thousands
of investors and executives from around the world to San Francisco.

Event: The 35^th Annual J.P. Morgan Healthcare
Conference Emerging Market Track
Date: January 11th, 2017
3pm (PST)
Location: Westin St. Francis Hotel, 335 Powell
Street, San Francisco, CA

About Genexine

Genexine,
Inc., listed on KOSDAQ (095700-KQ) since 2009, is a clinical stage
biotherapeutics company focused on immuno-oncology and
metabolic/autoimmune diseases. Genexine has robust pipelines in clinical
and pre-clinical stages based on long-acting Fc fusion technology and
therapeutic DNA vaccine technology. In the clinical stage, Genexine has
GX-H9 (long-acting human growth hormone, hGH-hyFc) for both adult and
pediatric GHD, currently in multinational phase II trials. GX-188E
therapeutic DNA vaccine for HPV-associated diseases is in Phase II in
Europe and Korea for Cervical Intraepithelial Neoplasia II/III and plans
to enter into Phase 1b/2a trial in cervical cancer with GX-188E in
combination Keytruda (anti- PD-1 therapy) of Merck (also known as MSD)
1H of 2017. Currently Genexine is running over 8 clinical trials from
Phase I to Phase IIb in Europe and Asia. In addition to Merck (MSD)
collaboration, Genexine has strategic partnerships with leading Asian
companies such as Shanghai Fosun Pharma, Tasly Pharma, Kalbe Pharma
(largest healthcare Indonesian company), and Korean big Pharma companies
such as Green Cross and Yuhan. Founded in 1999, Genexine has over 150
employees and half of them are scientists with MSc or Ph.D. Genexine is
located in Pangyo Techno Valley near Seoul, Korea with a branch office
in New York.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161228005157/en/